Morning Research on Sanofi, Keryx Biopharma, VIVUS, and Array BioPharma

   Morning Research on Sanofi, Keryx Biopharma, VIVUS, and Array BioPharma

PR Newswire

LONDON, March 27, 2013

LONDON, March 27, 2013 /PRNewswire/ --

Drug manufacturers and biotechnology companies are adapting to the changing
market dynamics for the healthcare industry. One of the major trends to emerge
in the healthcare industry in the last year has been increasing competition
from generic drugs. For companies such as Sanofi SA (NYSE: SNY), Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX), VIVUS Inc. (NASDAQ: VVUS), and Array
Biopharma Inc. (NASDAQ: ARRY), the key will be to boost their product pipeline
in the wake of increasing generic competition. Meanwhile, the healthcare
industry is also evaluating the impact of President Obama's Affordable Care
Act (ACA), which was upheld by the Supreme Court last year. Healthcare stocks
ended on a mixed note on Tuesday even as the broad market rallied, with the
Dow Jones closing at yet another record high. StockCall has posted free
technical research reports on SNY, KERX, VVUS, and ARRY and these can be
accessed by signing up at

http://www.stockcall.com/analysis

Shares of Sanofi SA rose sharply in trading on Tuesday, tracking gains in the
broad market. The stock rose to an intra-day high of $50.73 before finishing
the day 1.08% higher at $50.54 on above average volume of 3.46 million.
Sanofi's shares are currently trading close to their 52-week high of $50.93.
The stock has gained more than 6.60% so far in 2013. The company's shares are
also trading well above their 50-day and 200-day moving averages, which is a
bullish signal. Download the free report on SNY upon registration at

http://www.StockCall.com/SNY032713.pdf

Keryx Biopharmaceuticals Inc.'s shares struggled in Tuesday's trading session,
extending their losses from previous trading session. The stock finished the
day 1% lower at $6.90 on volume of 1.35 million, taking its gains in the last
three sessions to 1.85%. Keryx's shares have had an excellent run so far in
2013, gaining more than 163%. The gains came in late January; however, since
then the stock has struggled. Its MACD is currently trading below the signal
line, which is a bearish signal. KERX technical report can be accessed for
free by signing up at

http://www.StockCall.com/KERX032713.pdf

Shares of VIVUS Inc. fell sharply in trading on Tuesday even as the broad
market rallied. VIVUS' shares fell to an intra-day low of $10.39 before
finishing the day 2.83% lower at $10.63 on volume of 2.09 million. The
company's shares have been facing stiff resistance at $11. The stock currently
has support at $10. The stock's MACD chart is currently trading below the
zero-line, which is a bearish signal. The stock is also trading well below its
50-day and 200-day moving averages, which further confirms the bearish trend.
The free report on VVUS can be downloaded by signing up now at

http://www.StockCall.com/VVUS032713.pdf

Shares of Array Biopharma Inc. rallied in trading on Tuesday, closing 6.25%
higher at $4.93 on above average volume of 1.26 million. Array's shares have
now gained more than 32.50% for the year, outperforming the S&P 500, which has
gained more than 9.60% in the same period. The stock has seen a series of
highs in the last few sessions, which is a bullish signal. The stock has also
broken through $4.50 resistance level, which further confirms the positive
trend. Free report on ARRY can be accessed by registering at

http://www.StockCall.com/ARRY032713.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST – 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.